je.st
news
Home
› Humacyte Receives Fast Track Designation For HumaGraft For Vascular Access In Hemodialysis Program
Humacyte Receives Fast Track Designation For HumaGraft For Vascular Access In Hemodialysis Program
2014-07-30 10:52:33| drugdiscoveryonline Home Page
Humacyte, Inc., a pioneer in regenerative medicine, has announced that the U.S. Food and Drug Administration (FDA) has designated the HumaGraft development program for vascular access in hemodialysis patients as a Fast Track Development Program
Tags: program
access
fast
track
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||